Alebund Pharmaceuticals receives FDA clearance for kidney disease trial
September 10, 2026 | 11:01
Alebund Pharmaceuticals received U.S. Food and Drug Administration investigational new drug clearance to commence clinical trials for AP308, targeting treatment of IgA nephropathy kidney disease.
Mobile Version